Genotype specific age related changes in a transgenic rat model of Huntington's disease

We aimed to characterize the transgenic Huntington rat model with in vivo imaging and identify sensitive and reliable biomarkers associated with early and progressive disease status. In order to do so, we performed a multimodality (DTI and PET) longitudinal imaging study, during which the same TgHD and wildtype (Wt) rats were repetitively scanned. Surprisingly, the relative ventricle volume was smaller but increased faster in TgHD compared to Wt animals. DTI (mean, axial, radial diffusivity) revealed subtle genotype-specific aging effects in the striatum and its surrounding white matter, already in the presymptomatic stage. Using ¹⁸F-FDG and ¹⁸F-Fallypride PET imaging, we were not able to demonstrate genotype-specific aging effects within the striatum. The outcome of this longitudinal study was somewhat surprising as it demonstrated a significant differential aging pattern in TgHD versus Wt animals. Although it seems that the TgHD rat model does not have a sufficient expression of disease yet at the age of 12 months, further validation of this model is highly beneficial since there is still an incomplete understanding of the early disease mechanisms of Huntington's disease.

[1]  Christopher A. Ross,et al.  Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.

[2]  Erwan Dupont,et al.  In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy , 2010, Epilepsia.

[3]  G. Pearlson,et al.  Longitudinal change in basal ganglia volume in patients with Huntington's disease , 1997, Neurology.

[4]  Andreas Bauer,et al.  Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation , 2005, Journal of neurochemistry.

[5]  P. Basser,et al.  Estimation of the effective self-diffusion tensor from the NMR spin echo. , 1994, Journal of magnetic resonance. Series B.

[6]  Johan Nuyts,et al.  Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Ronald Wetzel,et al.  Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. , 2006, Human molecular genetics.

[8]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[10]  P Jeffrey Conn,et al.  [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot. , 2009, Nuclear medicine and biology.

[11]  Philippe Hantraye,et al.  Applications of lentiviral vectors for biology and gene therapy of neurological disorders. , 2008, Current gene therapy.

[12]  Paul Cumming,et al.  Endogenous competition against binding of [18F]DMFP and [18F]fallypride to dopamine D2/3 receptors in brain of living mouse , 2010, Synapse.

[13]  John L Bradshaw,et al.  A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  Jim Mintz,et al.  Myelin Breakdown and Iron Changes in Huntington’s Disease: Pathogenesis and Treatment Implications , 2007, Neurochemical Research.

[15]  Christian Beaulieu,et al.  Diffusion anisotropy in subcortical white matter and cortical gray matter: Changes with aging and the role of CSF‐suppression , 2004, Journal of magnetic resonance imaging : JMRI.

[16]  Nick C Fox,et al.  Increased rate of whole-brain atrophy over 6 months in early Huntington disease , 2006, Neurology.

[17]  A. Aron,et al.  Contrasting gray and white matter changes in preclinical Huntington disease , 2010, Neurology.

[18]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[19]  Nick C Fox,et al.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.

[20]  A. Leemans,et al.  Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract , 2009, NMR in biomedicine.

[21]  Mario Mascalchi,et al.  Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. , 2004, Radiology.

[22]  Francesca Cicchetti,et al.  Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease , 2005, Journal of the Neurological Sciences.

[23]  Young T. Hong,et al.  Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement , 2007, Science.

[24]  K. Lim,et al.  Age‐related decline in brain white matter anisotropy measured with spatially corrected echo‐planar diffusion tensor imaging , 2000, Magnetic resonance in medicine.

[25]  R. Ferrante,et al.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials. , 2009, Biochimica et biophysica acta.

[26]  V Bullman,et al.  Automated three‐dimensional analysis of particle measurements using an optical profilometer and image analysis software , 2003, Journal of microscopy.

[27]  R H Myers,et al.  Quantitative neuropathological changes in presymptomatic Huntington's disease , 2001, Annals of neurology.

[28]  C. Beaulieu,et al.  Determinants of anisotropic water diffusion in nerves , 1994, Magnetic resonance in medicine.

[29]  W C Eckelman,et al.  Experiment assessment of mass effects in the rat: implications for small animal PET imaging. , 2004, Nuclear medicine and biology.

[30]  Jan Sijbers,et al.  A complementary diffusion tensor imaging (DTI)-histological study in a model of Huntington's disease , 2012, Neurobiology of Aging.

[31]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[32]  Marios Politis,et al.  Hypothalamic involvement in Huntington's disease: an in vivo PET study. , 2008, Brain : a journal of neurology.

[33]  Jogeshwar Mukherjee,et al.  Evaluation of Dopamine D-2 Receptor Occupancy by Clozapine, Risperidone, and Haloperidol In Vivo in the Rodent and Nonhuman Primate Brain Using 18F-Fallypride , 2001, Neuropsychopharmacology.

[34]  David F Meaney,et al.  Traumatic Axonal Injury Results in Biphasic Calpain Activation and Retrograde Transport Impairment in Mice , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[36]  Andrea Ciarmiello,et al.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  R N Gunn,et al.  Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.

[38]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[39]  David S Tuch,et al.  Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures , 2006, Movement disorders : official journal of the Movement Disorder Society.

[40]  Thomas Walther,et al.  Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.

[41]  R. Albin,et al.  Rodent genetic models of Huntington disease , 2008, Neurobiology of Disease.

[42]  Shu-Wei Sun,et al.  Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging , 2005, Experimental Neurology.

[43]  G. Egan,et al.  Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease , 2008, Brain Research Reviews.

[44]  Yasin Temel,et al.  Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel , 2006, Behavioural Brain Research.

[45]  Yasin Temel,et al.  Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats , 2006, Neurobiology of Disease.

[46]  Kurt E. Weaver,et al.  Longitudinal diffusion tensor imaging in Huntington's Disease , 2009, Experimental Neurology.

[47]  A. Alexander,et al.  Diffusion tensor imaging of the brain , 2007, Neurotherapeutics.

[48]  Olaf Riess,et al.  Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. , 2007, The Journal of comparative neurology.

[49]  Derek K. Jones,et al.  Diffusion‐tensor MRI: theory, experimental design and data analysis – a technical review , 2002 .

[50]  John Missimer,et al.  Dynamic imaging of striatal D2 receptors in mice using quad-HIDAC PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  Jane S. Paulsen,et al.  In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease , 2004, Neurology.

[52]  M. Senda,et al.  KF 18446 PET in the rat brain after quinolinic acid lesion : Comparison with the dopamine receptor imaging , 2002 .

[53]  Jane S. Paulsen,et al.  Brain Structure in Preclinical Huntington’s Disease , 2006, Biological Psychiatry.

[54]  S. Aoki,et al.  Magnetic resonance , 2012, International Journal of Computer Assisted Radiology and Surgery.

[55]  Timothy Edward John Behrens,et al.  In vivo evidence for the selective subcortical degeneration in Huntington's disease , 2009, NeuroImage.

[56]  R H Myers,et al.  Decreased Neuronal and Increased Oligodendroglial Densities in Huntington's Disease Caudate Nucleus , 1991, Journal of neuropathology and experimental neurology.

[57]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[58]  Sarah A. J. Reading,et al.  Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study , 2005, Psychiatry Research: Neuroimaging.

[59]  A. Rego,et al.  Mechanisms of neurodegeneration in Huntington’s disease , 2008, The European journal of neuroscience.

[60]  Andreas Bauer,et al.  Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. , 2008, Human molecular genetics.

[61]  P. V. van Zijl,et al.  A motion correction scheme by twin‐echo navigation for diffusion‐weighted magnetic resonance imaging with multiple RF echo acquisition , 1998, Magnetic resonance in medicine.

[62]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[63]  Olaf Riess,et al.  Cellular and subcellular localization of Huntington aggregates in the brain of a rat transgenic for Huntington disease , 2007 .

[64]  John Russell,et al.  Dysmyelination Revealed through MRI as Increased Radial (but Unchanged Axial) Diffusion of Water , 2002, NeuroImage.

[65]  Jogeshwar Mukherjee,et al.  Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [18F]fallypride and [18F]desmethoxyfallypride , 2011, Synapse.

[66]  Vincent Frouin,et al.  Automated Three-Dimensional Analysis of Histological and Autoradiographic Rat Brain Sections: Application to an Activation Study , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[67]  Klaus Seppi,et al.  Diffusion‐weighted imaging in Huntington's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[68]  Jeffrey H Kordower,et al.  Animal models of Huntington's disease. , 2007, ILAR journal.

[69]  Alan C. Evans,et al.  Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease , 2008, NeuroImage.

[70]  Keiichi Oda,et al.  Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging , 2002, Annals of nuclear medicine.

[71]  Jun Yoshino,et al.  Demyelination increases radial diffusivity in corpus callosum of mouse brain , 2005, NeuroImage.

[72]  C. Beaulieu,et al.  The basis of anisotropic water diffusion in the nervous system – a technical review , 2002, NMR in biomedicine.

[73]  B. Escalante,et al.  Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation , 2002, Brain Research.

[74]  Michael I. Miller,et al.  Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images , 2010, NeuroImage.